Sarasota, FL -- (SBWIRE) -- 03/14/2019 -- Zion Market Research has published a new report titled "Pneumonia Therapeutics Market by Therapeutics (Prevention Vaccines and Treatment Drugs) and by Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy): Global Industry Perspective, Comprehensive Analysis, and Forecast, 2018–2025". According to the report, the global pneumonia therapeutics market accounted for USD 13.91 billion in 2018 and is expected to reach approximately USD 23.99 billion by 2025, at a CAGR of around 8.1% between 2019 and 2025.

Request Free Sample Report @ https://www.zionmarketresearch.com/sample/pneumonia-therapeutics-market

Pneumonia is an inflammatory condition that affects the air sacs or alveoli in the lungs and may further lead to dry cough, chest pain, fever, breathing trouble, etc. It is generally caused by germs and bacteria and mainly affects the person already suffering from cold and flu. Various bacteria, fungi, and viruses are responsible for causing pneumonia. It can be life-threatening for infants, young children, and elderly people. It can be diagnosed with the help of blood tests, X-rays, physical examinations, etc. Vaccination helps in the prevention of pneumonia, whereas patients with severe condition patient need to be hospitalized and treated with oxygen therapy. Generally, antibiotics like quinolones, macrolides, etc. are used for treating pneumonia.

The global pneumonia therapeutics market is growing due to increasing air pollution and rising geriatric population across the globe. Environmental factors are also considered major factors for the growth of pneumonia therapeutics market globally. Various environmental wastes like chemicals catalyze the growth of fungi, virus, and bacteria. These microorganisms cause pneumonia. According to the World Health Organization, more than 1.6 million annual deaths of children under the age of five are caused by pneumonia. However, the lack of awareness among the population about diagnosis and treatment and traditional treatment for pneumonia may restrain the growth of the global pneumonia therapeutics market in the future.

Based on therapeutics, the global pneumonia therapeutics market is segmented into prevention vaccines and treatment drugs. The prevention vaccines held the largest market share in terms of revenue in 2018, due to their high efficacy and precautionary effects. The treatment drugs segment is likely to show moderate growth in the years ahead, due to the wide availability of generic forms and growing resistance of antibiotics. Based on the distribution channel, the market is classified into hospital pharmacy, online pharmacy, and retail pharmacy.

By region, North America is expected to witness the highest CAGR over the forecast time period. This growth can be attributed to the increasing air pollution and growing release of hazardous chemicals in the environment. In Europe, the mortality rates for pneumonia are substantially higher in children up to four years and in adults aged 75 or over as compared to other age groups. This growth is mainly due to the increasing geriatric population and lifestyle-related ailments.

Download Free PDF Research Report Brochure @ https://www.zionmarketresearch.com/requestbrochure/pneumonia-therapeutics-market

Some key participants operating in the global pneumonia therapeutics market include GlaxoSmithKline, Sanofi, Merck & Co. Inc., Novartis AG, Eli Lilly and Company, AstraZeneca, Merck & Co., Pfizer, Baxter International Inc., Allergan, and Lupin Pharmaceuticals Inc., among others.

This report segments the global pneumonia therapeutics market into:

Global Pneumonia Therapeutics Market: Therapeutics Analysis

Prevention Vaccines
Treatment Drugs

Global Pneumonia Therapeutics Market: Distribution Channel Analysis

Hospital pharmacy
Retail pharmacy
Online pharmacy

Inquiry more about this report @ https://www.zionmarketresearch.com/inquiry/pneumonia-therapeutics-market

Global Pneumonia Therapeutics Market: Regional Analysis

North America
The U.S.
Europe
UK
France
Germany
Asia Pacific
China
Japan
India
Latin America
Brazil
The Middle East and Africa